| First Author | Choi HJ | Year | 2022 |
| Journal | Mol Brain | Volume | 15 |
| Issue | 1 | Pages | 63 |
| PubMed ID | 35850693 | Mgi Jnum | J:326882 |
| Mgi Id | MGI:7315867 | Doi | 10.1186/s13041-022-00948-1 |
| Citation | Choi HJ, et al. (2022) Donepezil ameliorates Abeta pathology but not tau pathology in 5xFAD mice. Mol Brain 15(1):63 |
| abstractText | The cholinesterase inhibitor donepezil is used to improve Abeta pathology and cognitive function in patients with Alzheimer's disease (AD). However, the impact of donepezil on tau pathology is unclear. Thus, we examined the effects of donepezil on Abeta and tau pathology in 5xFAD mice (a model of AD) in this study. We found that intraperitoneal injection of donepezil (1 mg/kg, i.p.) exhibited significant reductions in Abeta plaque number in the cortex and hippocampal DG region. In addition, donepezil treatment (1 mg/kg, i.p.) reduced Abeta-mediated microglial and, to a lesser extent, astrocytic activation in 5xFAD mice. However, neither intraperitoneal/oral injection of donepezil nor oral injection of rivastigmine altered tau phosphorylation at Thr212/Ser214 (AT100), Thr396, and Thr231 in 5xFAD mice. Surprisingly, we observed that intraperitoneal/oral injection of donepezil treatment significantly increased tau phosphorylation at Thr212 in 5xFAD mice. Taken together, these data suggest that intraperitoneal injection of donepezil suppresses Abeta pathology but not tau pathology in 5xFAD mice. |
